DrugPatentWatch Database Preview

Details for Patent: 9,000,021

Which drugs does patent 9,000,021 protect, and when does it expire?

Patent 9,000,021 protects BENDEKA and is included in one NDA.

This patent has thirteen patent family members in five countries.

Summary for Patent: 9,000,021

Title:	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Abstract:	Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.
Inventor(s):	Sundaram; Srikanth (Somerset, NJ), Tarriff; Scott L. (Mahwah, NJ)
Assignee:	Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ)
Application Number:	13/838,267
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,000,021
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 9,000,021

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;IV (INFUSION)	208194-001	Dec 7, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 9,000,021

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,597,398	Formulations of bendamustine	➤ Sign Up
9,572,887	Formulations of bendamustine	➤ Sign Up
9,034,908	Formulations of bendamustine	➤ Sign Up
9,597,397	Formulations of bendamustine	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 9,000,021

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2867295	➤ Sign Up
Canada	2867343	➤ Sign Up
China	104271135	➤ Sign Up
China	104302291	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 9,000,021

For more information try a trial or see the plans and pricing